Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia.
Department of Pulmonology, Postgraduate Medical Institute, Peshawar, Pakistan.
Am J Ther. 2018 Sep/Oct;25(5):e533-e540. doi: 10.1097/MJT.0000000000000421.
Although Pakistan has a high burden of multidrug-resistant tuberculosis (MDR-TB), little is known about prevalence, management, and risk factors for adverse drug reactions (ADRs) in MDR-TB patients in Pakistan. To evaluate occurrence, management, and risk factors for ADRs in MDR-TB patients, and its impact on treatment outcomes, this observational cohort study was conducted at programmatic management unit for drug resistant TB of Lady Reading Hospital Peshawar, Pakistan. A total of 181 MDR-TB patients enrolled at the study site from January 1, 2012 to February 28, 2013 were included. Patients with drug resistant TB other than MDR-TB, transferred out patients and those who were still on treatment at the end of study duration (January 31, 2015) were excluded. Patients were followed until treatment outcomes were reported. ADRs were determined by laboratory data and/or clinical criteria. SPSS 16 was used for data analysis. A total of 131 patients (72.4%) experienced at least 1 ADR. Gastrointestinal disturbance was the most commonly observed adverse event (42%), followed by psychiatric disturbance (29.3%), arthralgia (24.3%), and ototoxicity (21%). Potentially life-threatening ADRs, such as nephrotoxicity (2.7%) and hypokalemia (2.8%) were relatively less prevalent. Owing to ADRs, treatment regimen was modified in 20 (11%) patients. On multivariate analysis, the only risk factor for ADRs was baseline body weight ≥ 40 kg (OR = 2.321, P-value = 0.013). ADRs neither led to permanent discontinuation of treatment nor adversely affected treatment outcomes. Adverse effects were prevalent in current cohort, but caused minimal modification of treatment regimen, and did not negatively impact treatment outcomes. Patient with baseline body weight ≥ 40 kg should be closely monitored.
尽管巴基斯坦的耐多药结核病(MDR-TB)负担沉重,但对于该国 MDR-TB 患者中不良反应(ADR)的患病率、管理和危险因素知之甚少。为了评估 MDR-TB 患者中 ADR 的发生、管理和危险因素,及其对治疗结局的影响,本观察性队列研究在巴基斯坦白沙瓦莱迪夫人读医院耐药结核病规划管理单位进行。共有 181 名 2012 年 1 月 1 日至 2013 年 2 月 28 日期间在研究地点登记的 MDR-TB 患者被纳入本研究。排除了除 MDR-TB 以外的耐药结核病患者、转院患者和研究结束时仍在接受治疗的患者(2015 年 1 月 31 日)。对患者进行随访,直至报告治疗结局。ADR 通过实验室数据和/或临床标准确定。采用 SPSS 16 进行数据分析。共有 131 名患者(72.4%)至少经历了 1 次 ADR。胃肠道紊乱是最常见的不良事件(42%),其次是精神障碍(29.3%)、关节炎(24.3%)和耳毒性(21%)。相对较少见的潜在危及生命的 ADR 包括肾毒性(2.7%)和低钾血症(2.8%)。由于 ADR,有 20 名(11%)患者修改了治疗方案。多变量分析显示,ADR 的唯一危险因素是基线体重≥40kg(OR=2.321,P 值=0.013)。ADR 既未导致治疗永久性中断,也未对治疗结局产生不利影响。当前队列中不良反应普遍存在,但导致治疗方案的最小修改,且未对治疗结局产生负面影响。基线体重≥40kg 的患者应密切监测。